<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SARC-E (1 of 6) GIST</strong> Internal request: Institutional Review comment requesting the panel to consider including pazopanib.</td>
<td>Based on the data in the noted reference, the panel consensus was unanimous to include pazopanib for GIST.</td>
<td>Ganjoo KN, Villalobos VM, Kamaya A., et al. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol. 2014 Jan;25(1):236-40.</td>
<td>YES 13</td>
</tr>
<tr>
<td><strong>SARC-E (2 of 6)</strong> Internal request: Institutional Review comment requesting the panel to consider including temsirolimus.</td>
<td>Based on the data in the noted reference(s), the panel consensus was unanimous to include temsirolimus for PEComa Therapy.</td>
<td>Benson C, Vitfell-Rasmussen J, Maruzzo M, et al. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer Res. 2014 Jul;34(7):3663-8. Italiano A, Delcambre C, Hostein I, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol. 2010 May;21(5):1135-1137.</td>
<td>YES 13</td>
</tr>
</tbody>
</table>